AstraZeneca: Sustained operational strength leads to an upgrade

Published on 05/20/2025 at 10:42

Alphavalue

AstraZeneca: Sustained operational strength leads to an upgrade

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about AstraZeneca PLC

AstraZeneca RSV jab offers protection for premature babies in England	06:30am	AN
Foreign firms' executives entangled in Chinese probes	Jul. 18	RE
Foreign firms' executives entangled in Chinese probes	Jul. 18	RE
FTSE 100 closes up despite "harsh" UK jobs data	Jul. 17	AN
FTSE 100 closes up despite "harsh" UK jobs data	Jul. 17	AN
AstraZeneca, Daiichi Sankyo Win FDA Breakthrough Therapy Designation for Breast Cancer Drug	Jul. 17	MT
AstraZeneca: ninth breakthrough designation for Enhertu	Jul. 17
Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer	Jul. 17	CI
London stocks end lower on fears over Fed independence, focus turns to jobs data	Jul. 16	RE
London stocks end lower on fears over Fed independence, focus turns to jobs data	Jul. 16	RE
European Equities Close Mixed in Wednesday Trading; UK Inflation Rises 3.6%	Jul. 16	MT
Britain's life sciences plan gets mixed reception from pharma industry	Jul. 16	RE
Alexion Announces Update on CARES Phase III Clinical Programme of Anselamimab in Light Chain Amyloidosis	Jul. 16	CI
Astrazeneca's Anselamimab Misses Primary Goal in Phase III Amyloidosis Trial, Shares Down	Jul. 16	MT
AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study	Jul. 16	RE
AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study	Jul. 16	RE
ASTRAZENECA : JP Morgan remains its Buy rating	Jul. 16	ZD
AstraZeneca rare disease antibody shy of main goal in trial	Jul. 16	AN
AstraZeneca's Anselamimab Treatment Fails to Reach Primary Goal in Late-Stage Trial	Jul. 16	DJ
AstraZeneca: mixed phase III trial results for anselamimab	Jul. 16
AstraZeneca Says Phase 3 Trial for Amyloidosis Medication Fails to Meet Primary Endpoint	Jul. 16	MT
AstraZeneca drug fails main goal of late-stage amyloidosis study	Jul. 16	RE
AstraZeneca's Anselamimab in AL amyloidosis did not meet primary endpoint in overall patient population	Jul. 16	RE
Barclays: AstraZeneca's Q2 Results to Demonstrate 'Resilience' Amid Headwinds	Jul. 15	MT
European Equities Close Mixed in Monday Trading; EU Signals Readiness to Retaliate Against US Tariffs	Jul. 14	MT